Success rates in phase II and phase III clinical trials are recognized as two of the most powerful drivers of overall efficiency in drug development (Nat. Rev. Drug Disc. 23, 656–657; 2024). With the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback